These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38279684)

  • 1. Efficacy and safety of 40 mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study.
    Otsuki A; Inoshima N; Tochigi K; Ito H; Nakashima K
    Thorac Cancer; 2024 Mar; 15(7):570-574. PubMed ID: 38279684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
    Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
    Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
    JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report.
    Imai T; Yoshida T; Ohe Y
    Thorac Cancer; 2024 Mar; 15(9):749-751. PubMed ID: 38379439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
    Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
    Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the
    Furuta H; Uemura T; Yoshida T; Kobara M; Yamaguchi T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Sakao Y; Yatabe Y; Hida T
    Anticancer Res; 2018 Sep; 38(9):5231-5237. PubMed ID: 30194172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
    Wang K; Du R; Myall NJ; Lewis WE; Uy N; Hong L; Skoulidis F; Byers LA; Tsao A; Cascone T; Pozadzides J; Tu J; Negrao MV; Gibbons DL; Park K; Rinsurongkawong W; Lee JJ; Gandara D; Behl D; Shu CA; Riess JW; Baik C; Wakelee HA; Vaporciyan AA; Heymach JV; Zhang J; Le X
    J Thorac Oncol; 2024 Mar; 19(3):500-506. PubMed ID: 38012986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
    Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
    Hayashi H; Yonesaka K; Nakamura A; Fujimoto D; Azuma K; Sakata S; Tachihara M; Ikeda S; Yokoyama T; Hataji O; Yano Y; Hirano K; Daga H; Okada H; Chiba Y; Sakai K; Nishio K; Yamamoto N; Nakagawa K
    Lung Cancer; 2022 Jun; 168():38-45. PubMed ID: 35477147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
    Nokihara H; Ogino H; Mitsuhashi A; Kondo K; Ogawa E; Ozaki R; Yabuki Y; Yoneda H; Otsuka K; Nishioka Y
    BMC Cancer; 2022 Jun; 22(1):597. PubMed ID: 35650550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.
    Boosman RJ; Jebbink M; Veldhuis WB; Groenland SL; van Veggel BAMH; Moeskops P; de Langen AJ; Beijnen JH; Smit EF; Huitema ADR; Steeghs N
    Pharm Res; 2022 Oct; 39(10):2507-2514. PubMed ID: 35978149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.